NYSE: ARQT - Arcutis Biotherapeutics

Yield per half year: +44.72%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Arcutis Biotherapeutics

Extended chart Simple chart
Financial Markets by TradingView

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., биофармацевтическая компания, специализируется на разработке и коммерциализации средств лечения дерматологических заболеваний. Его ведущим кандидатом на продукт является ARQ-151, крем с рофлумиластом для местного применения, который прошел III фазу клинических испытаний для лечения псориаза бляшек и атопического дерматита.

more details
Компания также разрабатывает ARQ-154, формулу рофлумиласта в виде пены для местного применения для лечения себорейного дерматита и псориаза волосистой части головы; ARQ-252, селективный местный ингибитор янус-киназы типа 1 при экземе рук и витилиго; и ARQ-255, состав ARQ-252 для местного применения, предназначенный для более глубокого проникновения в кожу для лечения очаговой алопеции. Компания ранее была известна как Arcutis, Inc. и сменила название на Arcutis Biotherapeutics, Inc. в октябре 2019 года. Arcutis Biotherapeutics, Inc. была зарегистрирована в 2016 году, ее штаб-квартира находится в Вестлейк-Виллидж, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-01-31
ISIN US03969K1088
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://www.arcutis.com
Цена ао 13.71
Change price per day: +1.84% (13.6)
Change price per week: +9.23% (12.68)
Change price per month: -7.61% (14.99)
Change price per 3 month: +58.29% (8.75)
Change price per half year: +44.72% (9.57)
Change price per year: +186.16% (4.84)
Change price per 3 year: -16.42% (16.57)
Change price per 5 year: -45.71% (25.51)
Change price per 10 year: 0% (13.85)
Change price per year to date: -6.8% (14.86)
All parameters

Underestimation

Title Value Grade
P/S 3.6 5
P/BV 2.42 6
P/E 0 0
EV/EBITDA -1.39 0
Total: 5.13

Efficiency

Title Value Grade
ROA, % -76.79 0
ROE, % -295.65 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.8466 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 1517.09 10
Yield Ebitda, % 429.69 10
Yield EPS, % 215.81 10
Total: 10
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
03.02.2025 03.02.2025 Burnett Patrick
Officer		 Purchase 12.7 153 873 12116 0 0.02 link
03.02.2025 03.02.2025 Edwards Larry Todd
Officer		 Purchase 12.7 27 597 2173 0 0 link
03.02.2025 03.02.2025 Matsuda Masaru
Officer		 Purchase 28.98 241 635 8338 0 0.02 link
03.02.2025 03.02.2025 Watanabe Todd Franklin
Officer		 Purchase 12.7 245 123 19301 0 0.04 link
31.12.2024 31.12.2024 Burnett Patrick
See Remarks		 Sale 14 23 674 1691 0 0 link
15.11.2024 18.11.2024 Burnett Patrick
See Remarks		 Sale 10.03 1 003 100 0 0 link
14.11.2024 18.11.2024 Burnett Patrick
See Remarks		 Sale 10.29 711 307 69126 0 -0.14 link
24.09.2024 25.09.2024 Topper David Joseph
Chief Financial Officer		 Sale 9.48 110 214 11626 0 -0.02 link
24.09.2024 24.09.2024 Topper David Joseph
Officer		 Purchase 9.48 110 214 11626 0 0.02 link
01.07.2024 02.07.2024 Welgus Howard G.
Director		 Sale 9.31 93 100 10000 0 -0.02 link
01.07.2024 02.07.2024 Welgus Howard G.
Director		 Purchase 1.68 16 800 10000 0 0.02 link
28.05.2024 29.05.2024 Matsuda Masaru
See Remark		 Sale 9.01 15 993 1775 0 0 link
01.12.2023 01.12.2023 Watanabe Todd Franklin
See Remarks		 Purchase 1.68 100 002 59525 0 0.12 link
31.05.2023 01.12.2023 Watanabe Todd Franklin
See Remarks		 Purchase 6.38 9 334 1463 0 0 link
17.04.2023 18.04.2023 Welgus Howard G.
Director		 Sale 13.97 118 745 8500 0 -0.02 link
17.04.2023 18.04.2023 Welgus Howard G.
Director		 Purchase 1.68 14 280 8500 0 0.02 link
14.02.2023 15.02.2023 Watanabe Todd Franklin
See Remarks		 Sale 17.02 8 799 517 0 0 link
13.02.2023 15.02.2023 Watanabe Todd Franklin
See Remarks		 Sale 17 8 211 483 0 0 link
08.07.2022 12.07.2022 Watanabe Todd Franklin
President and CEO		 Sale 25.37 342 495 13500 0 -0.03 link
08.07.2022 12.07.2022 Watanabe Todd Franklin
President and CEO		 Purchase 1.68 11 906 7087 0 0.01 link
08.07.2022 12.07.2022 OSBORNE DAVID W
Chief Technical Officer		 Sale 25.41 55 826 2197 0 0 link

Institutions Volume Share, %
Jennison Associates LLC 9066082 9.36
Frazier Life Sciences Management, L.P. 8764232 9.05
Suvretta Capital Management, LLC 8473101 8.75
Rubric Capital Management LP 6644530 6.86
Polar Capital Holdings PLC 6297688 6.5
Morgan Stanley 6083072 6.28
Blackrock Inc. 5916546 6.11
Vanguard Group Inc 4896513 5.06
Franklin Resources, Inc. 4655544 4.81
Bain Capital Life Sciences Investors, LLC 3000000 3.1

ETF Share, % Profitability for 1 year, % Dividends, %
Virtus LifeSci Biotech Clinical Trials ETF 0.86056 63.04 0.33
Direxion Daily S&P Biotech Bull 3x Shares 0.22739 4067.92 0.25924
Future Tech ETF 0.11397 426.34 0.8416
Principal Healthcare Innovators ETF 0.11397 618.5 0.8416
Invesco Nasdaq Biotechnology ETF 0.11297 28.58 0.8565
Nuveen ESG Small-Cap ETF 0.1099 13.91 1.41019
Vanguard Russell 2000 Growth ETF 0.09 23.05 0.60264
ProShares Ultra Nasdaq Biotechnology 0.08002 51.7 0.85651
iShares Russell 2000 Growth ETF 0.07984 38.04 0.6026
iShares ESG Aware MSCI USA Small-Cap ETF 0.05784 18.09 1.49366
Vanguard Russell 2000 ETF 0.04 17.16 1.48801
Schwab U.S. Small-Cap ETF 0.02855 17.47 1.51433
ProShares UltraPro Russell2000 0.0233 89.82 1.47873
Fidelity MSCI Health Care Index ETF 0.01582 3 1.46057
ProShares Hedge Replication ETF 0.00673 5.92 1.47892
Humankind US Stock ETF 0.00451 18.81 1.99919
SPDR Portfolio MSCI Global Stock Market ETF 0.0021 17.99 2.19607
Schwab U.S. Broad Market ETF 0.00187 24.86 1.43354
iShares Russell 3000 ETF 0.0017 24.83 1.43482
Avantis U.S. Equity ETF 0.00006 23.04 1.59151
Vanguard Russell 3000 ETF 0 31.87 1.43817



Head Job title Payment Year of birth
Dr. Patrick E. Burnett M.D., Ph.D. Senior VP & Chief Medical Officer 689.95k 1972 (53 years)
Ms. Courtney Barton VP and Chief Compliance Officer & Privacy Officer N/A 1983 (42 years)
Mr. Todd Franklin Watanabe M.A. President, CEO & Director 1.01M 1968 (57 years)
Dr. Bhaskar Chaudhuri Ph.D. Co-Founder & Independent Director 59.67k 1955 (70 years)
Mr. Masaru Matsuda Esq., J.D. Senior VP, General Counsel & Corporate Secretary 626.22k 1971 (54 years)
Mr. Rajvir Madan Chief Digital & Technology Officer N/A
Ms. Amanda Sheldon Head of Corporate Communications N/A
Ms. Latha Vairavan Vice President of Finance & Investor Relations N/A
Mr. L. Todd Edwards Senior VP & Chief Commercial Officer 1964 (61 year)
Mr. David J. Topper Senior VP & Chief Financial Officer 1958 (67 years)

Address: United States, Westlake Village, CA , 3027 Townsgate Road - open in Google maps, open in Yandex maps
Website: http://www.arcutis.com